DNA methylation markers to predict treatment success of biologicals in Crohn’s disease.

€9.38M EUR

Funder	European Commission
Recipient Organization	Stichting Amsterdam Umc
Country	Netherlands
Start Date	Jan 01, 2023
End Date	Dec 31, 2026
Duration	1,460 days
Number of Grantees	18
Roles	Participant; Associated Partner; Coordinator
Data Source	European Commission
Grant ID	`101095449`

Grant Description

Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid arthritis (RA), and psoriasis (PsO).

Current therapeutics include antibodies (“biologicals”) targeting inflammatory proteins such as Tumor Necrosis Factor (adalimumab), leukocyte trafficking (vedolizumab), or IL-12/IL-23 (ustekinumab). At present however, it cannot be predicted which biological will be effective in an individual patient, with only

All Grantees

Stichting Vu; Universiteit Gent; Descin Bv; Diagenode; Twist Bioscience Coorporation; Alimentiv Bv; European Federation of Crohn'S and Ulcerative Colitis Associations; Belgian Ibd Research and Development; Stichting Amsterdam Umc; Horaizon Technology B.V.; Instituto de Medicina Molecular Joao Lobo Antunes; The Chancellor, Masters and Scholars of the University of Oxford; Asphalion Sl; Univerzitetni Klinicni Center Ljubljana; Szegedi Tudomanyegyetem; Genome Diagnostics B.V; King's College London; Universita Vita-Salute San Raffaele